Trials / Completed
CompletedNCT01530620
Efficacy and Tolerability of Propiverine Hydrochloride in Patients With Neurogenic Detrusor Overactivity
Efficacy and Tolerability of Propiverine Hydrochloride Extended Release (ER) Compared to Immediate Release (IR) in Patients With Neurogenic Detrusor Overactivity. A Randomized, Double Blind, Parallel Group, Multicenter Clinical Trial
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 66 (actual)
- Sponsor
- APOGEPHA Arzneimittel GmbH · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this clinical study is to compare efficacy and safety of propiverine hydrochloride extended and immediate release formulations in patients suffering from neurogenic detrusor overactivity.
Conditions
- Neurogenic Urinary Bladder Disorder
- Urinary Bladder, Neurogenic
- Bladder Disorder, Neurogenic
- Urinary Bladder Disorder, Neurogenic
- Neurogenic Bladder Disorder
- Urinary Bladder Neurogenic Dysfunction
- Urologic Diseases
- Overactive Detrusor Function
- Urinary Incontinence
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Propiverine hydrochloride ER (extended release) | 45 mg capsule (1x1/d) |
| DRUG | Propiverine hydrochloride IR (immediate release) | 15 mg tablet (3x1/d) |
Timeline
- Start date
- 2004-12-01
- Primary completion
- 2005-06-01
- Completion
- 2006-07-01
- First posted
- 2012-02-10
- Last updated
- 2012-02-10
Locations
3 sites across 3 countries: Austria, Germany, Romania
Source: ClinicalTrials.gov record NCT01530620. Inclusion in this directory is not an endorsement.